Search

Your search keyword '"Gomes-Silva, Beatriz"' showing total 5 results
Start Over Author "Gomes-Silva, Beatriz"
5 results on '"Gomes-Silva, Beatriz"'

1. Comparison of in Silico Strategies to Prioritize Rare Genomic Variants Impacting RNA Splicing for the Diagnosis of Genomic Disorders

Author

Rowlands, Charlie, primary, Thomas, Huw B, additional, Lord, Jenny, additional, Wai, Htoo A, additional, Arno, Gavin, additional, Beaman, Glenda, additional, Sergouniotis, Panagiotis, additional, Gomes-Silva, Beatriz, additional, Campbell, Christopher, additional, Gossan, Nicole, additional, Hardcastle, Claire, additional, Webb, Kevin, additional, O’Callaghan, Christopher, additional, Hirst, Robert A, additional, Ramsden, Simon, additional, Jones, Elizabeth, additional, -Smith, Jill Clayton, additional, Webster, Andrew R, additional, Douglas, Andrew GL, additional, O’Keefe, Raymond T, additional, Newman, William G, additional, Baralle, Diana, additional, Black, Graeme CM, additional, and Ellingford, Jamie M, additional

Published
2021
Full Text
View/download PDF

2. Comparison of in silico strategies to prioritize rare genomic variants impacting RNA splicing for the diagnosis of genomic disorders.

Author

Rowlands, Charlie, Thomas, Huw B., Lord, Jenny, Wai, Htoo A., Arno, Gavin, Beaman, Glenda, Sergouniotis, Panagiotis, Gomes-Silva, Beatriz, Campbell, Christopher, Gossan, Nicole, Hardcastle, Claire, Webb, Kevin, O'Callaghan, Christopher, Hirst, Robert A., Ramsden, Simon, Jones, Elizabeth, Clayton-Smith, Jill, Webster, Andrew R., Genomics England Research Consortium, and Ambrose, J. C.

Subjects
RNA splicing, DIAGNOSIS, DIAGNOSIS methods, FUNCTIONAL analysis
Abstract

The development of computational methods to assess pathogenicity of pre-messenger RNA splicing variants is critical for diagnosis of human disease. We assessed the capability of eight algorithms, and a consensus approach, to prioritize 249 variants of uncertain significance (VUSs) that underwent splicing functional analyses. The capability of algorithms to differentiate VUSs away from the immediate splice site as being 'pathogenic' or 'benign' is likely to have substantial impact on diagnostic testing. We show that SpliceAI is the best single strategy in this regard, but that combined usage of tools using a weighted approach can increase accuracy further. We incorporated prioritization strategies alongside diagnostic testing for rare disorders. We show that 15% of 2783 referred individuals carry rare variants expected to impact splicing that were not initially identified as 'pathogenic' or 'likely pathogenic'; one in five of these cases could lead to new or refined diagnoses. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

3. Nanoparticles in the Use of Natural Products for the Treatment of Lung Cancer

Author

Gomes Silva, Beatriz, Pereira da Silva, Wellington Francisco, Santos Soares, José Cleberson, Lima Cavalcanti, Iago Dillion, De Souza, Ivone Antônia, and Lima Cavalcanti

Subjects
Productos Biológicos, Biological Products, Lung Neoplasms, Neoplasias pulmonares, Nanopartículas, Nanoparticles, respiratory system, respiratory tract diseases
Abstract

Objective: Carry out a bibliographical survey about the use of nanoparticles in the delivery of natural products for the treatment of lung cancer. Methods: A bibliographic review was made using the descriptors “Nanoparticles”, “Biological Products” and “Lung Neoplasms”, through the databases ScienceDirect, PubMed and SciELO, in the period from 2009 to 2018. Results: After analyzing the articles according to the inclusion criteria, we obtained 31 articles, of which 25.81% refer to natural products in the treatment of lung cancer, 29.03% to nanoparticles in the treatment of lung cancer and 45.16 % to nanoparticles as carriers of natural products for the treatment of lung cancer. Conclusion: The use of nanoparticles allows the delivery of natural products, increasing their therapeutic properties against lung cancer cells, and decreasing the side effects of these highly toxic agents., Objetivo: Realizar un estudio bibliográfico sobre el uso de nanopartículas en el transporte de productos naturales para el tratamiento del cáncer de pulmón. Métodos: Se realizó una revisión bibliográfica utilizando los descriptores “Nanoparticles”, “Biological Products” y “Lung Neoplasms”, a través de las bases de datos ScienceDirect, PubMed y SciELO, en el período comprendido entre 2009 y 2018. Resultados: Después del análisis de los artículos de acuerdo con los criterios de inclusión, obtuvimos 31 artículos, de los cuales 25.81% hacían referencia a productos naturales en el tratamiento del cáncer de pulmón, el 29.03% a nanopartículas en el tratamiento del cáncer de pulmón y un 45.16 % a nanopartículas como agentes transportadores de productos naturales para el tratamiento del cáncer de pulmón. Conclusión: El uso de nanopartículas permite el transporte de productos naturales, aumentando sus propiedades terapéuticas contra las células de cáncer de pulmón, además de disminuir los efectos secundarios de estos agentes altamente tóxicos.

Published
2019

5. Nanoparticles in the Use of Natural Products for the Treatment of Lung Cancer.

Author

Lima Cavalcanti, Iago Dillion, Santos Soares, José Cleberson, da Silva, Wellington Francisco Pereira, Gomes Silva, Beatriz, and de Souza, Ivone Antônia

Subjects
NANOPARTICLES, BIOLOGICAL products, LUNG tumors, LUNG cancer treatment, TOXINS
Abstract

Copyright of Ars Pharmaceutica is the property of Facultad de Farmacia de Granada and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results